



(51) International Patent Classification:

C07D 213/75 (2006.01) C07D 403/04 (2006.01)

A61P 11/00 (2006.01) C07D 403/12 (2006.01)

C07D 239/69 (2006.01) A61K 31/495 (2006.01)

C07D 241/22 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/060176

(22) International Filing Date:

12 November 2020 (12.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/934,287 12 November 2019 (12.11.2019) US

(71) Applicant: GENZYME CORPORATION [US/US]; 50

Binney Street, Cambridge, MA 02142 (US).

(72) Inventors: GAO, Zhongli; c/o Sanofi 55 Corporate Drive,

Mail Code: 55A-525, Bridgewater, NJ 08807 (US). HURL-

BUT, Gregory; c/o Sanofi 55 Corporate Drive, Mail Code:

55A-525, Bridgewater, NJ 08807 (US). LIAO, Junkai; c/o

Sanofi 55 Corporate Drive, Mail Code: 55A-525, Bridgewater,

NJ 08807 (US). MUNSON, Mark; c/o Sanofi 55 Corporate

Drive, Mail Code: 55A-525, Bridgewater, NJ 08807

(US).

(74) Agent: HALEY, Christopher, K. et al.; Goodwin Procter LLP,

100 Northern Avenue, IP Docketing Dept./7th Fl,

Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,


TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY



(I)

(57) Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

